Navigation Links
Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
Date:2/4/2009

GAITHERSBURG, Md. and ATLANTA, Feb 4 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, and Expression Therapeutics, a biotechnology company specializing in factor VIII-based therapeutics, today announced a collaborative agreement to co-develop novel cell and protein therapies for Hemophilia A.

Hemophilia A is an inherited blood clotting disorder caused by a mutation in the factor VIII gene resulting in a deficiency of factor VIII protein. Lentigen and Expression Therapeutics will develop two types of treatments for Hemophilia: a novel chimeric factor VIII protein for direct injection and a cell therapy that may permanently correct the disorder.

"Hemophilia A is a serious disease, affecting about one in 10,000 people worldwide," explained Dr. Boro Dropulic, President and Chief Scientific Officer of Lentigen. "The two therapeutic approaches leverage Lentigen's technology in two important areas: protein expression and cell therapy. Factor VIII is a difficult protein to manufacture but Lentigen's protein expression technology will permit the production of a novel human factor VIII protein at levels highly favorable for commercialization. Secondly, Expression Therapeutics' proprietary factor VIII will be used in a novel stem cell therapy for Hemophilia A that aims to restore the clotting capability of patients suffering from this debilitating disease.

"The platform technology developed by Expression Therapeutics will be used to advance the treatment of hemophilia A. By combining our high expression factor VIII technology with Lentigen's protein expression and gene transfer capabilities, we are confident Lentigen is the ideal partner to help bring this technology to the clinic and marketplace," stated Dr. Trent Spencer, President of Expression Therapeutics.

Tim Ravenscroft, Lentigen's Chief Executive Officer, commented, "We are excited to be working with Expression Therapeutics on factor VIII treatments. The projects are consistent with our strategy of applying Lentigen's technology in diseases of high unmet therapeutic need."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Collaborations include The National Institutes of Health, PATH, The University of Pennsylvania, Invitrogen, ThermoFisher Scientific and The U.S. Army. For further information, visit www.lentigen.com.

About Expression Therapeutics

Expression Therapeutics, LLC is a privately owned biotechnology company in Atlanta focused on the development of products that will improve the standard of treatment for individuals with hemophilia A. The high-expression factor VIII technology developed by Expression Therapeutics can be used in the development of both protein replacement and cell therapy-based therapeutics. For further information, visit www.expressiontherapeutics.com

    Lentigen Media Contacts:
    Richard Lewis Communications, Inc. (212) 827-0020
    Gregory Tiberend, gtiberend@rlcinc.com
    Cecelia Heer, cheer@rlcinc.com

    Expression Therapeutics Media Contacts:
    Gabriela Denning, gdenning@expressiontherapeutics.com (678) 278-1140
    Keith Kerstann, kwkerstann@expressiontherapeutics.com


'/>"/>
SOURCE Lentigen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
2. Lentigen Corporation Announces Relocation to New Facility
3. Lentigen Appoints Jim Meade as Vice President of Corporate Development
4. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
5. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
6. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
7. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
8. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
9. VIRxSYS and Lentigen Announce Litigation Settlement
10. New technique allows simultaneous tracking of gene expression and movement
11. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... OH (PRWEB) , ... August 16, 2017 , ... ... a beneficial microbe delivery system, announced it has secured $2M in funding from ... Queen City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar ...
(Date:8/16/2017)... and OXFORD, England , Aug. 16, 2017 ... for biotech executive search and leadership development, and Virdis Group, ... have created an exclusive alliance that enables clients to leverage ... "For our clients here in the ... access to a diverse population of leadership talent throughout the ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics , ... development, announces the launch of the new NHS Agile biosensor chip . ... data for a wide range of molecules, including small and large molecules, peptides, ...
(Date:8/15/2017)... ... 2017 , ... Kenall, a leader in sealed solid-state lighting, ... sealed and perform efficiently for years. The downlights are ideal for a variety ... such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food and pharmaceutical processing ...
Breaking Biology Technology:
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):